Irina Bilous

Associate Writer, Neuroscience, Clinical Trials

Iryna Bilous, M.S., is a biotechnologist and neuroscientist. She has experience in developing cutting the edge neuroscience techonology - novel brain implants, along with this she was involved in brain activity and behavior research. Iryna's current primary focus is on immunooncology, as she is a part of a clinical operations team in a growing biotech start-up.

Contributing Author

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Irina

10 Companies Shaping the Brain-Computer Interface Landscape: Invasive vs Non-Invasive BCI Technology

The brain–computer interface (BCI) technology domain is constantly progressing as researchers and companies collaborate to devise inventive solutions that connect the human brain with external devices. This expanding sector, driven by the need for better communication, rehabilitation, and augmented cognitive …

Five AI-driven Drug Discovery Companies Enabling Precision Oncology

Artificial Intelligence (AI) is steadily making its presence felt across various sectors, including the pharmaceutical industry. Among the multiple applications of AI in this field, immunotherapy—a treatment method that utilizes the body's immune system to combat diseases, notably cancer—is seeing …

Notable Trends and Companies to Follow in Neuroscience

Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for CNS assets from phase 1 through to regulatory submission was only 5–6%.

The failure of pharmaceutical companies to bring …

9 Notable AI Companies in Clinical Research to Watch in 2023

The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials …

How AI-Driven Multi-Omics is Reshaping Drug Discovery

The fusion of artificial intelligence (AI) with multi-omics - a comprehensive study encompassing genomics, transcriptomics, proteomics, metabolomics, and other related fields - is heralding an era of speedier, more efficient drug discovery. AI has been disrupting various sectors, but its …

VRG50635, a Drug Discovered Through Verge Genomics' AI-powered planform, Shows Promising Phase 1 Results for ALS Treatment

Verge Genomics, a frontrunner in the implementation of AI in drug discovery, recently concluded the Phase 1 clinical trial of VRG50635, an investigational drug for Amyotrophic Lateral Sclerosis (ALS). The drug, developed through artificial intelligence-driven methods, was well tolerated and …

IgGenix Advances Therapeutic Approach to Peanut Allergies with IgG4 Monoclonal Antibodies

IgGenix, Inc., a California-based preclinical antibody discovery and development company, recently reported advances towards a potential therapeutic solution for peanut allergies based on IgG4 monoclonal antibodies.

Harnessing AI for Drug Discovery Certara Amplifies CODEX Platform Capabilities

Certara, a leader in biosimulation, has recently expanded the horizons of AI in drug discovery with the introduction of artificial intelligence (AI) capabilities and data fabric connectivity to its clinical trials outcome analytics platform, CODEX.

Seqera Labs Joins Forces with Genomics England to Boost Genomic Medicine Research

Seqera Labs, recognized for its secure workflow orchestration software in the life sciences domain, is aligning forces with Genomics England, a government-owned entity, which initiated the notable 100,000 Genomes Project in alliance with the NHS. This collaboration aims to enhance …

Valo Therapeutics' Innovative Immuno-Oncology Therapy PeptiCRAd-1 Begins Human Trials

Valo Therapeutics Oy (ValoTx), a frontrunner in the development of advanced immunotherapies for cancer, has initiated its Phase I trial of PeptiCRAd-1, a pioneer in the realm of immuno-oncology. The first participant, enrolled in this Germany-based trial, has received the …